{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-021433","form_type":"8-K","ticker":"STXS","cik":"0001289340","company_name":"Stereotaxis, Inc.","filed_at":"2023-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.283112+00:00","generated_at":"2026-06-13T23:48:27.340965+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Stereotaxis to initiate first-in-human trial for MAGiC catheter after CE Mark clinical data request","bullets":["Notified body requests clinical data for MAGiC catheter CE Mark under EU MDR; prior submission included preclinical data.","First-in-human trial to commence to support CE Mark; Stereotaxis expects to complete study before end of 2023.","Company reiterates expectation of double-digit revenue growth in 2023; strong cash position.","CEO states innovation strategy includes accessible robot and proprietary catheters for EP and endovascular interventions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-021433","json":"https://secwatch.observer/filing/0001493152-23-021433.json","markdown":"https://secwatch.observer/filing/0001493152-23-021433.md","text":"https://secwatch.observer/filing/0001493152-23-021433.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1289340/000149315223021433/0001493152-23-021433-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1289340/000149315223021433/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T23:48:27.340965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}